CoChat

Bringing Buprenorphine‐Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

Open access
Amass, Leslie, Ling, Walter, Freese, Thomas E., Reiber, Chris, Annon, Jeffrey J., Cohen, Allan J., McCarty, Dennis, Reid, Malcolm S., Brown, Lawrence S., Clark, Cynthia, Ziedonis, Douglas M., Krejci, Jonathan, Stine, Susan, Winhusen, Theresa, Brigham, Greg, Babcock, Dean, Muir, Joan A., Buchan, Betty J., Horton, Terry · 2004 · The American Journal on Addictions
Cited by 147

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

In October 2002, the U.S. Food and Drug Administration approved buprenorphine‐naloxone (Suboxone®) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for Clinical Trials Network (CTN) sponsored two clinical trials assessing buprenorphine‐naloxone for short‐term opioid detoxification. These trials provided an unprecedented field test of its use in twelve diverse community‐based treatment programs. Opioid‐dependent men and women were randomized to a thirteen‐day buprenorphine‐naloxone taper regimen for short‐term opioid detoxification. The 234 buprenorphine‐naloxone patients averaged 37 years old and used mostly intravenous heroin. Direct and rapid induction onto buprenorphine‐naloxone was safe and well tolerated. Most patients (83%) received 8 mg buprenorphine‐2 mg naloxone on the first day and 90% successfully completed induction and reached a target dose of 16mg buprenorphine‐4 mg naloxone in three days. Medication compliance and treatment engagement was high. An average of 81% of available doses was ingested, and 68% of patients completed the detoxification. Most (80.3%) patients received some ancillary medications with an average of 2.3 withdrawal symptoms treated. The safety profile of buprenorphine‐naloxone was excellent. Of eighteen serious adverse events reported, only one was possibly related to buprenorphine‐naloxone. All providers successfully integrated buprenorphine‐naloxone into their existing treatment milieus. Overall, data from the CTN field experience suggest that buprenorphine‐naloxone is practical and safe for use in diverse community treatment settings, including those with minimal experience providing opioid‐based pharmacotherapy and/ or medical detoxification for opioid dependence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/10550490490440807

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 147

Metadata

Authors
Amass, L., Ling, W., Freese, T. E., Reiber, C., Annon, J. J., Cohen, A. J., McCarty, D., Reid, M. S., Brown, L. S., Clark, C., Ziedonis, D. M., Krejci, J., Stine, S., Winhusen, T., Brigham, G., Babcock, D., Muir, J. A., Buchan, B. J., & Horton, T.
Venue
The American Journal on Addictions
Publisher
Wiley
Published
2004-05-06
Volume
13
Issue
S1
Pages
S42-66
ISSN
  • 1055-0496 (ISSN-L)
  • 1521-0391
OpenAlex
W2145139215
Cited by
147
References
12
FWCI
10.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.